Alpha Lifetech Inc. was founded by a group of scientists with extensive experience in membrane protein production, nanobody discovery, monoclonal development, and other pharmaceutical pre-development services. Based on our several technology service platforms, Alpha Lifetech Inc. has launched nearly 10,000 high-quality spot membrane protein reagents, cytokines, drug target antibodies and other related reagents. Whether you're working in the fields of immunology, cell biology, molecular biology, or any other scientific discipline, Alpha Lifetech's comprehensive range of research products will help you achieve accurate and reliable results. We pride ourselves on being able to offer a comprehensive set of high-quality products and services tailored to customer needs, which help advance the projects of scientific research institutions, academics, and enterprises in the life science industry.
Through tailored products, adaptable service and packaging choices, and unwavering support, Alpha Lifetech Inc. guarantees that researchers have access to the most fitting and efficient tools tailored to their research endeavors.
Our team of experienced scientists works closely with customers to design and execute tailored strategies for nanobody discovery via alpaca immunization, ensuring the generation of high-quality leads that align with project goals.
Antibody humanization from a broad range of parental species including mouse, rat, rabbit, llama, and avian.
Our Membrane Proteomics platform offers a comprehensive solution for the identification, quantification, and characterization of membrane proteins, providing valuable insights into their functions and interactions within the cell.
Alpha Lifetech can offer the native antibody libraries (scFv, Fab, VHH Formats and customized) from host animals like Goat, Camel and Llama.
Unlocking the unique biology of camelids to generate the world's smallest functional antibody fragments
Alpacas naturally produce heavy-chain-only antibodies (HCAbs) whose variable domains — called VHH or nanobodies — are only ~15 kDa. This unique biology makes alpaca immunization the gold standard starting point for nanobody discovery, generating highly diverse immune libraries with superior epitope access.
Due to their small size and extended CDR3 loops, nanobodies derived from alpaca immunization can access cryptic epitopes, enzyme active sites, and receptor clefts that are completely inaccessible to conventional IgG antibodies — dramatically expanding the druggable target space.
The alpaca immunization workflow — from antigen injection to immune VHH library construction — can be completed in as little as 6–8 weeks, significantly shorter than traditional hybridoma or phage display approaches, enabling faster project progression.
Nanobodies from alpaca immunization exhibit exceptional thermal stability (Tm often >70°C), tolerance to extreme pH, and high solubility. These properties make them ideal candidates for industrial biosensors, point-of-care diagnostics, and harsh-environment applications.
Nanobodies can be produced at scale in microbial expression systems (E. coli, yeast) at a fraction of the cost of full-length monoclonal antibodies. This manufacturability advantage is driving rapid commercial adoption across the biopharmaceutical and diagnostics industries.
Nanobodies serve as ideal building blocks for bispecific constructs, CAR-T cell therapies, antibody-drug conjugates (ADCs), and fusion proteins. Their single-domain nature enables straightforward genetic engineering and reformatting without loss of function.
A streamlined, end-to-end process from antigen design to validated nanobody leads
Recombinant protein, peptide, cell, or VLP antigen design and QC
Multi-round immunization protocol with titer monitoring by ELISA
Peripheral blood lymphocyte collection and RNA extraction
RT-PCR amplification and phage/yeast display library building (>10⁸ diversity)
Multiple rounds of biopanning followed by ELISA and SPR screening
Affinity, specificity, epitope binning, and functional assay validation
Sequence confirmed leads with full characterization data package
Alpha Lifetech Inc. is committed to providing the highest level of customer services, competitive pricing, speedy delivery, and a comprehensive, cutting-edge product offering. Our sales and technical support staff are available to help you select the right products and service solutions.
As a reliable supplier and partner, Alpha Lifetech Inc. always puts customers first. We cherish every opportunity to collaborate with worldwide customers in scientific exploration. Welcome to contact our technical support at any time.
Alpha Lifetech Inc. provides a wide range of technology platforms, including membrane protein, antibody discovery, single B cell sorting, and hybridoma technology. Whether you're engaged in immunology, cell biology, molecular biology, or any other scientific discipline, our comprehensive suite of services is designed to empower you with precise and dependable results.
Our years of manufacturing experience and refined products provide you with better protection
Nanobody discovery via alpaca immunization is reshaping the global biopharmaceutical and diagnostics markets
The global nanobody therapeutics market was valued at over USD 1.2 billion in 2023 and is projected to grow at a CAGR exceeding 22% through 2030. This explosive growth is driven by the regulatory approval of Caplacizumab (Cablivi®) — the first approved nanobody drug — and a robust pipeline of over 40 nanobody-based candidates in clinical trials.
Alpaca immunization remains the cornerstone of immune VHH library generation for pharmaceutical-grade nanobody discovery. Major CDMOs and biotech companies are investing heavily in dedicated alpaca facilities and high-throughput immunization protocols to meet surging demand from oncology, infectious disease, and rare disease programs.
The diagnostics sector represents another major growth driver, with nanobodies enabling ultra-sensitive lateral flow assays, digital ELISA platforms, and PET imaging agents that outperform conventional antibody-based tools. The COVID-19 pandemic accelerated this trend, with multiple nanobody-based diagnostic products receiving emergency authorization globally.
40+ nanobody-based drug candidates in clinical trials; first approved nanobody drug generating >$300M annually
Nanobodies replacing conventional antibodies in ELISA, LFA, and digital immunoassay platforms for superior sensitivity
Nanobody-functionalized electrochemical and optical biosensors enabling real-time environmental and food safety monitoring
VHH-based CARs and intrabodies driving next-generation CAR-T and CAR-NK cell therapies with improved tumor penetration
Nanobody-based crop protection agents and veterinary diagnostics leveraging the inherent stability of VHH fragments
From bench to bedside — how alpaca-derived nanobodies are transforming every stage of the biomedical value chain
Nanobodies derived from alpaca immunization against tumor-associated antigens (HER2, EGFR, PD-L1) are being engineered into bispecific T-cell engagers and CAR-T constructs. Their small size enables superior tumor penetration compared to full-length mAbs, while their single-domain format allows facile multimerization for avidity enhancement.
Alpaca-immunized VHH libraries against viral spike proteins (SARS-CoV-2, Influenza, RSV) have yielded potent neutralizing nanobodies with picomolar affinities. Inhaled nanobody formulations represent a revolutionary delivery modality for respiratory infections, enabled by the exceptional stability of VHH fragments.
Nanobodies targeting transferrin receptor (TfR) and LRP1 are being used as blood-brain barrier (BBB) shuttles, enabling delivery of therapeutic payloads to the CNS — a major unmet need in Alzheimer's, Parkinson's, and brain tumor treatment. Alpaca immunization provides the ideal starting material for generating high-affinity BBB-crossing nanobodies.
Nanobodies (also called "megabodies" when fused to rigid scaffolds) are indispensable tools for cryo-EM structure determination of challenging membrane proteins and GPCRs. Alpaca immunization against detergent-solubilized or nanodisc-reconstituted targets generates conformationally selective nanobodies that stabilize protein complexes for high-resolution imaging.
The thermal stability and compact format of alpaca-derived nanobodies make them ideal recognition elements for lateral flow assays (LFAs) and microfluidic diagnostic devices. Nanobody-based LFAs for troponin, procalcitonin, and infectious disease biomarkers demonstrate sensitivity matching laboratory ELISA at a fraction of the cost.
Nanobodies are being deployed as highly specific capture agents in bioreactor monitoring systems, enabling real-time quantification of product titer, host cell proteins, and process-related impurities. Their stability in harsh industrial conditions (high temperature, detergents, organic solvents) makes them superior to conventional antibodies for process analytical technology (PAT) applications.
Our platform utilizes phage and yeast display technology to develop different forms of antibodies: VHH single domain antibodies, Fab antibodies, and scFv antibodies, resulting in high affinity and high specificity antibodies.
Leveraging alpaca immunization as the primary immune source, our VHH discovery pipeline integrates next-generation sequencing (NGS)-guided library analysis, automated high-throughput screening, and AI-assisted hit prioritization to deliver validated nanobody leads with exceptional speed and confidence.
READ MOREEnd-to-end nanobody discovery services built on alpaca immunization and advanced display technologies
VHH Antibody Discovery Service
Fab Antibody Discovery Service
ScFv Antibody Discovery Service
Phage Display System
Phage Library Construction Service
Phage Display Screening Service
The aptamer platform provided by Alpha Lifetech includes two categories: aptamer synthesis platform, which mainly involves SELEX aptamer library synthesis service and aptamer development service, and aptamer screening platform including screening services based on SELEX technology for proteins, peptides, cells, small molecules, and other target molecules, as well as aptamer optimization and identification analysis services.
READ MORE
Aptamer Synthesis Platform
Aptamer Screening Platform
Aptamer Optimization Service
Aptamer Analysis Service
Aptamer Research Service
Our monoclonal antibody development services include three technologies: phage display technology, single-B cell technology, and hybridoma cell technology, which produce monoclonal antibodies for different species.
READ MORE
Single B Cell Sorting Platform
Hybridoma Technology Platform
Phage Display Technology Platform
Mouse mAb Development Service
Rabbit mAb Development Service
We also provide a series of technical services related to antibody engineering, stable cell line construction, yeast display, protein interaction analysis, etc., laying the foundation for antibody development.
READ MORE
Stable Cell Line Construction Service
Animal Immunization Platform
Protein Interaction Service
Yeast Display Library Construction Service
Yeast Display Library Screening Service
Alpha Lifetech's integrated alpaca immunization and VHH discovery platform delivers validated nanobody leads in as little as 10–14 weeks. From antigen design to fully characterized hits — we handle everything so you can focus on advancing your science.
Start Your Nanobody Project TodayWhat our global partners say about our nanobody discovery and alpaca immunization services
Exceptional Nanobody discovery capabilities from Alpha Lifetech. Their team's dedication to customer satisfaction and scientific excellence is evident in every interaction. Grateful for their partnership and looking forward to future collaborations!
— Riley HarperQuality products! Our experience with Alpha Lifetech has been nothing short of outstanding. The alpaca immunization protocol was flawlessly executed and delivered high-titer immune libraries on schedule.
— Stella GrantReliable, responsive, and results-driven — Alpha Lifetech. Their VHH discovery service exceeded our expectations in both hit rate and affinity of the identified nanobodies.
— Olivia WestSimply put, Alpha Lifetech delivers. Their dedication to customer satisfaction and quality service is unmatched, and we're grateful to have them as a trusted partner in our nanobody-based drug discovery program.
— Ava MitchellThe nanobodies we obtained through Alpha Lifetech's alpaca immunization service demonstrated exceptional specificity and thermal stability — exactly what we needed for our biosensor application.
— Dr. James ChenAlpha Lifetech's integrated platform — from alpaca immunization to phage display panning and hit characterization — saved us months of development time. Highly recommended for any nanobody discovery project.
— Dr. Sarah MüllerComprehensive antibody development services — from alpaca immunization to lead nanobody characterization